Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The cardiovascular effects of peroxisome proliferator-activated receptor agonists.

Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, Poirier P, Reoch J, Eisenberg MJ.

Am J Med. 2012 Feb;125(2):126-33. doi: 10.1016/j.amjmed.2011.08.025. Review.

PMID:
22269613
2.

The cardiovascular effects of peroxisome proliferator-activated receptor agonists.

Kolatkar NS.

Am J Med. 2013 Mar;126(3):e11. doi: 10.1016/j.amjmed.2012.04.044. No abstract available.

PMID:
23410570
3.

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.

Wilding JP.

Diabetes Obes Metab. 2012 Nov;14(11):973-82. doi: 10.1111/j.1463-1326.2012.01601.x. Epub 2012 Apr 23. Review.

PMID:
22443197
4.

The reply.

Friedland S, Filion KB, Eisenberg MJ.

Am J Med. 2013 Mar;126(3):e13. doi: 10.1016/j.amjmed.2012.10.016. No abstract available.

PMID:
23410571
5.

Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.

Cavender MA, Lincoff AM.

Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.

PMID:
20653327
6.

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ.

Cardiovasc Diabetol. 2005 Sep 16;4:14. Review.

7.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
8.

Evolution of peroxisome proliferator-activated receptor agonists.

Chang F, Jaber LA, Berlie HD, O'Connell MB.

Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22. Review.

PMID:
17519293
9.
10.

Examining the safety of PPAR agonists - current trends and future prospects.

Bortolini M, Wright MB, Bopst M, Balas B.

Expert Opin Drug Saf. 2013 Jan;12(1):65-79. doi: 10.1517/14740338.2013.741585. Epub 2012 Nov 8. Review.

PMID:
23134541
11.
12.

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.

Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M.

BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180.

13.

Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE.

Am Heart J. 2013 Sep;166(3):429-34. doi: 10.1016/j.ahj.2013.05.013. Epub 2013 Jul 26.

PMID:
24016490
14.

PPAR agonists and the metabolic syndrome.

Staels B.

Therapie. 2007 Jul-Aug;62(4):319-26. Epub 2007 Nov 6. Review.

PMID:
17983557
15.

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

Pershadsingh HA.

Expert Opin Investig Drugs. 2004 Mar;13(3):215-28. Review.

PMID:
15013941
16.

Discovery Approaches for Novel Dyslipidemia Drugs.

Maqbool F, Safavi M, Bahadar H, Rahimifard M, Niaz K, Abdollahi M.

Curr Drug Discov Technol. 2015;12(2):90-116. Review.

PMID:
26135857
17.

Reassessing the cardiovascular risks and benefits of thiazolidinediones.

Zinn A, Felson S, Fisher E, Schwartzbard A.

Clin Cardiol. 2008 Sep;31(9):397-403. doi: 10.1002/clc.20312. Review.

18.

Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

Chopra B, Georgopoulos NT, Nicholl A, Hinley J, Oleksiewicz MB, Southgate J.

Cell Prolif. 2009 Oct;42(5):688-700. doi: 10.1111/j.1365-2184.2009.00628.x. Epub 2009 Jul 10.

PMID:
19614673
19.
20.

Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.

Fogo AB.

Curr Opin Nephrol Hypertens. 2008 May;17(3):282-5. doi: 10.1097/MNH.0b013e3282f9b1c0. Review.

PMID:
18408479

Supplemental Content

Support Center